Abstract
Identification and characterisation of tumour associated antigens is a pre-requisite for an effective and targeted immunotherapy. Tumour antigens are used as markers to improve diagnosis and to predict the outcome of a cancer. This review emphasises on a few important cellular target molecules such as indoleamine 2,3-dioxygenase (IDO), interleukin- 15 (IL15), mucin 1 (MUC1) and Major histocompatibility complex class I related chain A and B (MICA/B) which are involved in the downstream pathways of cancer progression. Unique aberrant and over-expression of these molecular targets modulates the physiological and immunological micro-environments in the host tissue. IDO, IL15 and MICA/B provoke NK cell and dendritic cell mediated anti-tumour responses due to their strong binding affinity to activator receptors on the immune cells. The application of these random markers derived from immunological mechanisms may help to improve and delineate some of the predictive indicators obtained with random serum profiles.
Keywords: IDO - Indoleamine 2,3-dioxygenase, MIC - Major histocompatibility complex (MHC) class I related chain A, ADCC, –, Antibody dependent cellular cytotoxicity, AIDC, Activation induced cell death, MUC1, Mucin 1, TAA, Tumour associated antigen
Current Cancer Therapy Reviews
Title: NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Volume: 4 Issue: 2
Author(s): Renu Datta, Catherine L. Riley, Italo A. Dodi and Robert C. Rees
Affiliation:
Keywords: IDO - Indoleamine 2,3-dioxygenase, MIC - Major histocompatibility complex (MHC) class I related chain A, ADCC, –, Antibody dependent cellular cytotoxicity, AIDC, Activation induced cell death, MUC1, Mucin 1, TAA, Tumour associated antigen
Abstract: Identification and characterisation of tumour associated antigens is a pre-requisite for an effective and targeted immunotherapy. Tumour antigens are used as markers to improve diagnosis and to predict the outcome of a cancer. This review emphasises on a few important cellular target molecules such as indoleamine 2,3-dioxygenase (IDO), interleukin- 15 (IL15), mucin 1 (MUC1) and Major histocompatibility complex class I related chain A and B (MICA/B) which are involved in the downstream pathways of cancer progression. Unique aberrant and over-expression of these molecular targets modulates the physiological and immunological micro-environments in the host tissue. IDO, IL15 and MICA/B provoke NK cell and dendritic cell mediated anti-tumour responses due to their strong binding affinity to activator receptors on the immune cells. The application of these random markers derived from immunological mechanisms may help to improve and delineate some of the predictive indicators obtained with random serum profiles.
Export Options
About this article
Cite this article as:
Datta Renu, Riley L. Catherine, Dodi A. Italo and Rees C. Robert, NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310133
DOI https://dx.doi.org/10.2174/157339408784310133 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives
Current Pharmaceutical Biotechnology HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Unraveling Potential Candidate Targets Associated with Expression of p16<sup>INK4a</sup> or p16 Truncated Fragment by Comparative Proteomics Analysis
Current Proteomics Toll-Like Receptors in the Cycling Female Reproductive Tract and During Pregnancy
Current Women`s Health Reviews Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Meet Our Editorial Board Member:
Current Pharmaceutical Design Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome
Current Pharmaceutical Design Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Implication of CYP24A1 Splicing in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Fast Determination of β-estradiol by Chromatographic Method and its Application to Clinical Pharmacokinetics Studies
Current Pharmaceutical Analysis Genetics Talks to Epigenetics? The Interplay Between Sequence Variants and Chromatin Structure
Current Genomics